News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK) Announces Approval In Canada For Incruse™ Ellipta™ (Umeclidinium) As A Treatment For COPD



4/17/2014 4:37:25 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MISSISSAUGA, ON, April 17, 2014 /CNW/ - GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Incruse™ Ellipta™ (umeclidinium, as umeclidinium bromide) has received market authorisation in Canada for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. This is the first market authorisation granted for this product anywhere in the world.

Help employers find you! Check out all the jobs and post your resume.

Read at Canada NewsWire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES